In-vivo imaging of methionine metabolism in patients with suspected malignant pleural mesothelioma.

摘要: OBJECTIVES In-vivo characterization of malignant pleural mesothelioma (MPM) with C-methionine PET/computed tomography (MET PET). METHODS Between September 2014 and February 2016, 30 consecutive patients clinical suspicion MPM were prospectively recruited. The study was approved registered at www.clinicaltrials.gov (NCT02519049). Patients evaluated baseline MET PET (experimental) fluorine-18 fluorodeoxyglucose (FDG PET) (standard). Principal parameters analyzed SUVmax, SUVmean, metabolic tumor volume (MTV), burden (MTB  = MTV ×SUVmean). reference standard for diagnostic performance based on histology. RESULTS presence malignancy confirmed in 29/30 patients: 23 (76.6%) (20 epithelioid, two biphasic, one sarcomatoid), five (16.6%) adenocarcinoma the lung, (3.3%) an undifferentiated carcinoma. In case, diagnosis benign inflammation. All tumors showed increased uptake C-methionine: median MTV, MTB were, respectively, 5.70 [95% confidence interval (CI): 4.51-6.79], 3.15 (95% CI: 2.71-3.40), 33.85 14.08-66.64), 105.25 41.77-215.25). Pathology data revealed MTV to be significantly higher nonepithelioid histology (P < 0.05). other a homogeneous distribution across types. Overall, identified 49 lymph nodes, compared 34 nodes FDG PET, demonstrating sensitivity 91% 80-96%), positive predictive value 92% 82- 97%), accuracy 85% = 0.0042). CONCLUSIONS is able characterize lesions regardless This technique shows than identification secondary nodes.